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Objective: To assess the effects of facility-based interventions using existing resources to improve overall
patient attendance and adherence to antiretroviral therapy (ART) at ART-providing facilities in Uganda.
Methods: This was an interventional study which tracked attendance and treatment adherence of two distinct
cohorts: experienced patients who had been on treatment for at least 12 months prior to the intervention and
patients newly initiated on ART before or during the intervention. The interventions included instituting
appointment system, fast-tracking, and giving longer prescriptions to experienced stable patients. Mixed-
effects models were used to examine intervention effects on the experienced patients, while Cox proportional
hazards models were used to determine the intervention effects on time until newly treated patients
experienced gaps in medication availability.
Results: In all, 1481 patients’ files were selected for follow-up from six facilities   720 into the experienced
cohort, and 761 into the newly treated cohort. Among patients in the experienced cohort, the interventions
were associated with a significant reduction from 24.4 to 20.3% of missed appointments (adjusted odds ratio
(AOR): 0.67; 95% confidence interval (CI): 0.59 0.77); a significant decrease from 20.2 to 18.4% in the
medication gaps of three or more days (AOR: 0.69; 95% CI: 0.60 0.79); and a significant increase from 4.3 to
9.3% in the proportion of patients receiving more than 30 days of dispensed medication (AOR: 2.35; 95% CI:
1.91 2.89). Among newly treated patients, the interventions were associated with significant reductions of
44% (adjusted hazard rate (AHR): 0.56, 95% CI: 0.42 0.74) and 38% (AHR: 0.62; 95% CI: 0.45 0.85) in the
hazards of experiencing a medication gap of 7 and 14 days or more, respectively.
Conclusions: Patients’ adherence was improved with low-cost and easily implemented interventions using
existing health facilities’ resources. We recommend that such interventions be considered for scale-up at
national levels as measures to improve clinic attendance and ART adherence among patients in Uganda and
other low-resource settings in sub-Saharan Africa.
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I
n resource-limited settings, antiretroviral therapy
(ART) programs strive to maintain high numbers of
patients taking the life-long medications as countries
scale-up ART accessibility (1 5). Adherence to treatment
is one of the most important predictors of survival for
individuals with HIV and AIDS (6, 7). For most HIV
regimens, patients need to achieve  95% level of ad-
herence so as to avoid developing drug resistance (8).
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(page number not for citation purpose)For 95% adherence, missing even one pill in a week on
a regimen of two pills per day could lead to developing
resistance to therapy.
Several factors such as distance to health facilities,
availability and affordability of ARVs, lack of money
for transport and food, quality of life during ARV, long
waiting time, and congestion at health facilities influence
adherence to ART (8, 9). Some of these factors require
a programmatic approach, which may be difficult to
address in a number of resource-limited settings (10, 11).
Initiatives implemented at facility level, within facility
resources, can affect a large number of patients more
efficiently and are thus more sustainable. However, they
need to be easy to introduce, implement, and should
be affordable in terms of costs. In the past, initiatives
designed to improve adherence have included training
health personnel on ARTsupply chain management, HIV
prevention, clinical care, counseling, community support
programs, and use of experienced ART patients (expert
clients) who provide support to other patients who are
newly commencing treatment (6, 8). Frequently, such
initiatives rely on substantial financial inputs that are
often impossible to sustain by the health facilities in
resource-limited settings (8, 12).
The current health-care system in Uganda was pri-
marily designed for acute as opposed to chronic care. The
system could be adapted to deliver chronic care through
interventions targeted at improving clinic attendance and
ART adherence. Many health facilities offering ART ser-
vices lack systematic appointment systems, which results
in over-crowding when patients come early hoping to be
first to receive care. Subsequently, the congestion that
develops negatively affects the quality of services as well
as patient satisfaction with care (13). Furthermore, in
many clinics, experienced patients already stabilized on
ART are still required to present for care and go through
the entire clinical process even if the only reason for their
visit is to receive medication refills. To relieve congestion,
these patients could be fast tracked to the pharmacy and/
or dispensed longer durations of therapy.
In this study, we set out to determine the extent to
which a set of easily implemented health facility-based
interventions that used already existing resources at
health facilities, mainly designed to reduce clinic conges-
tion as well as patient waiting time, would improve clinic
attendance and adherence among patients seeking ART
services at Ugandan health facilities.
Methods
Study setting and design
Six district-level public hospitals previously determined
to have poor adherence performance to ART were
enrolled in this study based on the results of a previous
national survey (8). All of these clinics had poor clinic
flow, no or poor appointment systems, congested clinics
with long waiting times, medication gaps, or medications
not dispensed to patients after prescription (8, 9). These
health facilities were supervised by the Uganda Ministry
of Health (MoH) with ART funding from the Govern-
ment of Uganda and donor agencies, including the
Global Fund to Fight AIDS, Tuberculosis and Malaria
and the U.S. President’s Emergency Plan to Fight AIDS
Relief (PEPFAR).
This was designed as an interventional cohort study,
which tracked both experienced patients and those newly
initiated on antiretroviral drugs (ARVs) using facility-
based records. The major aim was to assess the impacts
of the interventions on patients’ clinic attendance and
adherence. Implemented over a period of 17 months in
2009 and 2010, the study consisted of collecting retro-
spectively pre-intervention data, an implementation phase
of the interventions, and follow-up visits to the health
facilities while prospectively collecting post-intervention
data. During the pre-intervention period, we also visited
each study facility to explain the purpose of the inter-
ventions to the clinic staff and to gain consensus on how
to conduct the intervention.
The effects of the interventions were assessed by fol-
lowing two groups of patients using their clinical and
dispensing records at the health facilities. In each facility,
one randomly chosen cohort composed of experienced
patients who had been on treatment at least 12 months
prior to the interventions, and who were still in treatment
6 months before baseline. The other cohort, consecutively
chosen, composed of all newly treated patients over
their first 4 months, who initiated treatment during the
6-months prior to the baseline up to 4 months before
the end of the follow-up period. After 4 months, these
patients were transferred into the experienced cohort.
The study was based on patients’ clinical records and
facility dispensing records that were selected based on the
criteria above. There was no direct involvement between
the research team and the patients
At each health facility, we instituted two facility-level
interventions. The impacts were measured at the patient
level through time series analysis. These interventions
aimed at improving patient flow and decongesting the
clinics. We did not include a control group as the
interventions implemented at the health facility level
affected every patient attending the same facility.
Description of the interventions
The first component of the interventions was to introduce
an appointment system and fast-track the ‘refill-only’
patients. Patients categorized as ‘refill only’ were experi-
enced patients, who had been on treatment for at least
12 months from baseline, with a self-reported record of
95% adherence to medication regimen. These were given
appointments to come for refill of medications only and
Celestino Obua et al.
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need to be seen by clinicians or counselors if they did not
report any complaints at triage. Traditionally, all patients
would be required to pass through all stages of the clinic
workflow, wherethey would bereviewedbythecounselors
and clinicians before being dispensed with refill medi-
cation. This was in spite of whether they had health
complaints or not, and would subsequently lead to clinic
congestions. The appointment system consisted of a book
where the next reviewdate would be recorded and patients
were encouraged to return on that particular date. An
appointment diary was also given to the patient to act as a
reminder. Thus, the clinicianswould be able to ascertain in
advance which patients to expect on any particular day,
and by the end of the clinic day, which patients had not
honored their appointments. Currently in most Ugandan
health facilities, patients are not given specific hours of
appointment on the review dates. Furthermore, electronic
dispensing is rare in the health facilities because of its
associated technological challenges.
The second component of the interventions was to
recommend that prescribers at the health facilities in-
crease the numbers of days of medicines dispensed (longer
prescription) from the traditional 30 60 days or 90 days
for patients considered by the clinicians to be 95%
adherent to their medication regimens. The aim was for
such patients to make less frequent visits to the clinic,
thus further reducing clinic congestion.
Health providers were provided with clear instructions
to counsel the patients to report any problems during
the scheduled visits or at any times without waiting for
appointment days. This was to ensure that the patients
remained in contact with clinicians at any time. In addi-
tion, the patients receiving longer prescription were to be
seen by the clinician at least once every 6 months even
when they had no complaints.
Apart from the above changes instituted bythe research
team, clinics continued to operate normally. The intro-
duction of the appointment diaries and the appointment
books provided the records of clinic attendance. The
facilities also used these data for identification and follow-
up of patientswho missed appointments. Two weeks prior
to implementing the interventions, we visited each study
facility to explain the purpose of the interventions to
the clinic staff and to gain consensus on how to con-
duct the intervention. After the intervention began, we
made fortnightly supervisory visits, supplemented by
telephone calls to ensure proper conduct throughout the
post-intervention period. The research team was not
directly involved in the practical implementation of the
interventions.
Sample selection
We aimed to follow a cohort of 100 experienced patients
per facility, as recommended in WHO manuals on
investigating longitudinal patterns of medication use
(14, 15). Anticipating a 20% loss to follow-up during
the study period, we thus set out to identify 125 ex-
perienced patients per facility. Assuming that a minimum
of 80% of the total of 600 patients would complete
all scheduled visits, this would mean a 95% confidence
interval (CI) of 94.5% on the sample-wide estimates of
monthly rates, which was our primary focus. For newly
treated patients, the sample size was determined by the
rate of treatment initiation at each facility. We aimed
to include all patients who were initiated on treatment
during the study period.
Data sources and data collection
Four research assistants used in this study were the same
ones used in the earlier studies (8, 9). They were trained
by the research team to retrieve prescription and clinical
records from the patient files and the dispensing records,
using methods recommended in the WHO manual on
investigating longitudinal patterns of drug use (14, 15).
They visited the health facilities with the intervention
team to collect data but did not interact with patients.
Data were collected from records in the clinic, pharmacy
and appointment registers/diaries. During the 11 months
of the post-intervention period, we collected data regard-
ing the patients’ appointment dates, actual return dates,
and the numbers of pills or days of medication dispensed.
From these data, we computed the proportion of missed
appointment and the days without medication (medica-
tion gaps) for each patient.
Outcome measures
The following indicators were used to assess the impact
of the interventions among the experienced cohort: the
proportion of patients with any scheduled visits missed;
the proportion of patients with more than 30 days
of dispensed medication days; and the proportion
of patients with 3 or more days without medication
(medication gap).
A different analysis was performed for the newly
treated cohort. This was because of the nature of enrol-
ment of patients into this cohort   where some were
enrolled during the post-intervention period. In this
cohort, we investigated the event-rates of the patients
experiencing a medication gap of seven or more days, and
of 14 or more days during the first 120 days of treatment.
Statistical analysis
We allowed 2 months after the initiation of the interven-
tion before collecting post-intervention data. In this
analysis, we have indicated this period as the ‘during’
period. The rationale was that the effects of the inter-
ventions would not accurately be measured immediately
after instituting them. The interventions however con-
tinued to be implemented until the end of the study
duration, overall 2 years.
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presented using frequency tabulations for categorical
variables, and descriptive summaries for the continuous
variables. To assess the intervention effect, we first con-
structed graphical representations for each study outcome
for the pre-, during and post-intervention periods. Overall
aggregates of these outcome data per intervention periods
have also been presented in tabular formats. We however
excluded the ‘during’ intervention data from the modeling
activities. For the experienced cohort, we modeled the
intervention effect using mixed-effects models for binary
responseswithexchangeablecorrelationstructure(16,17).
These models were adjusted for the patient-level demo-
graphic and clinical characteristics, including age, gender,
initial treatment regimen, and pre-ARTweight.
In the newly treated cohort, we used Cox proportional
hazards survival models to determine the differences in
event-rates of experiencing a medication gap of ]7d a y s
and ]14 days after commencing therapy before and after
the interventions. Patients were censored at the earliest of
the following dates: on experiencing the outcome of
interest; on the day of their last visit before reaching 120
days of treatment; or on the date of their last visit before
the start of the intervention (for those initiating therapy
withinthe pre-interventionperiod) or theend offollow-up
(for those initiating therapy within the post-intervention
period). We constructed the survival curves to depict the
fraction experiencing the outcome for ease of interpreta-
tion.Statisticalsignificanceforthedifferencesintheevent-
rates was assessed using the log-rank test. Cox propor-
tional hazard modelswere fitted to determine the adjusted
differences in survival between the intervention periods.
All analyses were performed using Stata/IC 10 (Stata
Corp., College Station, TX, USA). All statistical infer-
ences were assessed at the 5% type 1 error level, and all
p-values presented were based on two-tailed tests.
Ethical issues
Ethical clearance for the study was obtained from Makerere
University Faculty of Medicine Research and Ethics
Committee, while permission to conduct this study was
obtained from the Uganda National Council of Science
and Technology (UNCST). Consensus meetingswere held
with the heads of the health facilities before instituting the
interventions in the health facilities. During these meetings,
the practical implementation of the proposed interven-
tions was discussed, given the workflow and operational
settings of the health facilities would have to be adjusted.
Nowrittenorverbalconsentwassoughtfromthepatients,
since the interventions were implemented by regular
clinical staff at the facility from their routine records. No
specific data were obtained directly from the patients
during the study. The research team did not perform any
data collection in the communities. Furthermore, all data
were anonymized in all phases of data collection.
Results
Baseline characteristics of patients in the
experienced cohort
In total, 720 patients with an average age of 38.8 years
(SD910.2 years) comprising 468 (65%) females and
252 (35%) males were recruited into the experienced
cohort. Most patients (482/720, 67%) were aged 31 49,
most had commenced therapy with advanced disease
(540/720, 75% at WHO stages 3 or 4). The majority
(662/720, 92%) commenced treatment with the stavudine
(40) lamivudine nevirapine regimen (Table 1).
Baseline characteristics of patients in the newly
treated cohort
Overall, 761 patients (68% females) with an average age
of 35.8 years (SD912.5 years) were included in the
newly treated cohort. More than half (60%) commenced
Table 1. Demographic and clinical characteristics of patients
by cohort
Overall study population
(N 1,481)
Experienced
cohort
a (n 720)
Newly treated
cohort
b (n 761)
Gender, n (%)
Female 407 (65.2%) 315 (68.0%)
Male 217 (34.8%) 148 (32.0%)
Age in years, average (sd)
n (%)
38.8 (10.2%) 35.82 (12.5)
18 30 113 (19.0%) 147 (32.5%)
31 49 400 (67.1%) 252 (55.8%)
50 and older 83 (14.0%) 53 (11.7%)
WHO stage at ART
initiation, n (%)
Stage 1 31 (5.5%) 32 (8.5%)
Stage 2 110 (19.5%) 120 (31.8%)
Stage 3 371 (66.0%) 193 (52.0%)
Stage 4 51 (9.1%) 32 (8.5%)
Initial ART regimen, n (%)
AZT-3TC-EFV 5 (0.8%) 35 (7.5%)
AZT-3TC-NVP 35 (5.6%) 274 (58.8%)
TVD-EFV 2 (0.32%) 12 (2.6%)
TVD-NVP 1 (0.16%) 18 (3.9%)
d4T(30)-3TC-NVP 575 (91.9%) 114 (24.5%)
Others
c 8 (1.3%) 13 (2.8%)
Average (sd) weight at ART
initiation
53.35 (10.2) 51.35 (12.7)
Female 52.6 (10.3) 50.63 (11.5)
Male 54.0 (9.8) 52.81 (14.9)
aOn ART at least 6 months prior to the index visit.
bInitiated ART within 6 months prior to the follow-up period.
cOther regimens include TDF-3TC-NVP, d4T (30)-3TC-EFV, and
d4T (40)-3TC-NVP.
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regimens were zidovudine lamivudine nevirapine (59%)
and stavudine (30) lamivudine nevirapine (25%).
Impact of the interventions in the experienced cohort
Any scheduled visits missed
The percentage of experienced patients who missed any
scheduled appointments increased in the pre-intervention
period, and then declined moderately during the post-
intervention period (Fig. 1a). The decline was more
pronounced during the first 6 months of the intervention
before starting to rise again thereafter. The percentages of
missed scheduled appointments in the pre- and post-
intervention periods were 24.4 and 20.3%, respectively.
Overall, the interventions were associated with a signifi-
cant 33% reduction in the odds of missed visits (adjusted
odds ratio (AOR): 0.67; 95% CI: 0.59 0.77) among ex-
perienced patients (Table 2).
Patients with more than 30 days dispensed medication
After the interventions, there was an increase in the
percentage of patients receiving medicines for longer
periods at their scheduled refill (Fig. 1b). The percentage
of visits where patients received more than 30 days of medi-
cation refills increased from 4.3% in the pre-intervention
to 9.3% in the post-intervention period (Table 2). Overall,
the interventions were associated with a significant 2.4
times increase in the odds of experienced patients re-
ceiving more than 30 days of medication refills (AOR:
2.35; 95% CI: 1.91 2.89).
Patients with medication gaps of 3 days or more
The percentage of experienced patients who were re-
corded to have medication gaps of 3 days or more at each
visit declined over time (Fig. 1c). The percentages of visits
with medication gaps were 20.2% in the pre-intervention,
and 18.4% in the post-intervention period (Table 2).
Overall, the interventions were associated with a sig-
nificant 31% reduction in the odds of experiencing a
medication gap of three or more days (AOR: 0.69; 95%
CI: 0.60 0.79) among experienced patients.
Impact of the interventions in the newly
treated cohort
Generally, the cumulative probability of newly treated
patients experiencing long medication gaps was higher in
Fig. 1. (a) Unadjusted monthly rates of attendance, (b) long duration dispensing, and (c) adherence in the experienced cohort.
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intervention period (Fig. 2a). The rates per 1,000 person-
years of experiencing medication gaps of 7 or more days
was 7.7 (95% CI: 6.5 9.0) in the pre-intervention period
and 4.5 (95% CI: 3.6 5.6) in the post-intervention period
(log-rank p-value B0.0001). Similarly, the rates per 1,000
person-years of experiencing medication gaps of 14 or
more days was 4.8 (95% CI: 4.0 to 5.8) in the pre-
intervention period and 3.1 (95% CI: 2.4 4.1) in the post-
intervention period (log-rank p-value  0.0022). From
the adjusted Cox proportional hazards models, the inter-
ventions were associated with a significant 44% reduction
in the event-rates of experiencing medication gaps of
7 and more days (adjusted hazard rate (AHR): 0.56,
95% CI: 0.4 0.74), and a significant 38% reduction in the
event-rates of experiencing medication gaps of 14 and
more days (AHR: 0.62; 95% CI: 0.45 0.85) (Table 3).
Discussion
Our findings show that clinical quality can be improved
through a strategy whereby providers at facility level are
encouraged to implement simple and feasible interven-
tions to improve clinic patient flow that are adapted to
the resources at their own facility, combinedwith minimal
support supervision. We demonstrated a modest but
significant 17% relative decrease in the percentage of
patients who missed scheduled appointments. This trans-
lated into more patients keeping scheduled appointments,
and thus improving adherence amongst such patients.
Several studies have shown that appointment keeping is
important for treatment success among patients on ART
(18 20), and this study also demonstrated a decrease in
the number of patients who missed appointments over
time, although there was a tendency towards increase
again during the last few months of follow-up.
One of the interventions was to encourage clinicians
to increase the number of dispensed medication days
for patients who had demonstrated their ability to remain
consistently on therapy as a means to cut down the
number of clinic visits and thereby decongest the clinic.
We showed that the percentage of patients who were
dispensed medication for more than 30 days more than
doubled after the intervention. This practice has also
been implemented elsewhere with considerable success
(21 24). The greater than twofold increase in the pro-
portion of patients who had thirty and more days of
medication dispensed achieved in this study would help
reduce crowds at the clinic and make the care process
Table 2. Changes in adherence-based indicators over time for experienced
a patients
Unadjusted percent during period Adjusted intervention effects
Outcome
Pre-intervention
(%)
During
intervention (%)
Post
intervention (%)
Odds ratio
(95% CI) p
Any scheduled visits missed 24.4 21.4 20.3 0.67 (0.59, 0.77) B0.0001
Patients with  30 days dispensed
medication days
4.3 8.0 9.3 2.35 (1.91, 2.89) B0.0001
Patients with ]3 days medication gaps 20.2 15.0 18.4 0.69 (0.60, 0.79) B0.0001
aOn ART at least 6 months prior to the index visit.
Fig. 2. Probabilities of experiencing a medication gap of (a) ]7 days or (b) ]14 days during the ﬁrst 120 days of antiretroviral
treatment in the newly treated patient cohort.
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greater quantities of medication may be limited by low
stock levels or stock-outs in some resource-poor health
facilities. Although we did not determine the stock levels
of medicines at the facilities, this study has shown that
increased medication days can be an effective way to
decongest clinics and thereby improve adherence to ART
even in health facilities with limited resources.
The percentage of experienced patients, who had medi-
cation gaps of three or more days, decreased significantly
following the interventions. Among newly treated patients,
the interventions significantly reduced the likelihood of
experiencing a medication gap of seven or more days by
about one-half, and the risk of a medication gap of 14 or
more days by over one-third. The literature suggests that
three or more days without medication may predict
treatment failure among ART patients, while medication
gaps of 14 or more days have been reported to be related
to drug resistance development (25 27). The demonstrated
reduction in the risk of experiencing medication gaps
therefore shows that introducing a patient-appointment
system, fast-tracking experience stable patients through
the clinic, and dispensing larger prescriptions, makes the
clinic less congested improving overall attendance and
may be effectively executed as a way of improving patient
adherence and guarding against treatment failure.
Strengths and limitations
By engaging local health workers and empowering them
to implement simple systems changes in their clinics, this
study has shown that it is possible to improve patient
attendance and adherence to ART without any increase
in external resources. Introducing an appointment sys-
tem, fast-tracking experienced patients, and dispensing
larger prescriptions as part of routine service were
intended to improve clinic flow, reduce congestion, and
shortened clinic waiting time. These changes resulted in
modest but significant improvements in adherence in-
dicators. Other workers have shown that integrating
interventions into routine service delivery does not only
improve uptake of services but ensures sustainability (28).
The main strengths of the study are the design, the
low-resource interventions and the robust analysis. The
interventions were actively implemented by the staff at
the respective facilities and accepted into their routine.
They could be contextually adapted and institutionalized
to promote sustainability. The relatively modest effects on
attendance and adherence should be seen in light of the
minimal input of extra resources and the huge benefits
for those individuals, who maintain treatment. If the
same type of interventions would be implemented at a
national level with similar effects, another 15,000 20,000
of the 200,000 patients on treatment (29) would keep
their appointments and thereby experience a better
chance to stay adherent.
Despite the success of this approach, there are many
challenges inherent in implementing real-world interven-
tions in low-resource settings. Unfortunately, changes in
policy and programs during the study period were critical
events that may have affected the success of the inter-
ventions described in this study. For example, during the
implementation period, the guidelines for first-line ARVs
were changed. Many facilities were consequentially un-
able to consistently stock ARVs to support the new
regimens resulting in an increased rate of stock-outs, and
due to the retrospective nature of the study we were not
able to collect data on daily stock availability. In addition,
and most devastating, some ART support programs
curtailed their activities when funding from PEPFAR
was withdrawn (30), resulting in disruption of supply,
thus directly influencing access to medicines and atten-
dance. During the study, some facilities also introduced a
nutrition program, which competed for resources and
staff attention. However by reducing patient load using
the recommended interventions, this may have made
more time available for these other important tasks
without the need for more resources. Given all of these
external changes, it is remarkable that the simple meas-
ures resulted in meaningful and statistically significant
improvements in attendance and adherence.
Conclusions and recommendations
This study has demonstrated that easily implemented
interventions designed to reduce clinic crowding, such as
appointment systems, patient fast-tracking, and increas-
ing medication days, and where existing resources are
Table 3. Probabilities of experiencing medication gaps of ]7d a y so r]14 days during the ﬁrst 120 days of treatment among
newly treated patients
Event rate per 1,000 person years Adjusted proportional hazard estimates
Period Number of events Rate (95% CI) estimates Log-rank p-value Intervention effect (95% CI) p-value
]7 days Pre 145 7.68 (6.52, 9.04) B0.0001 [ref] B0.0001
Post 78 4.48 (3.58, 5.59) 0.56 (0.42, 0.74)
]14 days Pre 102 4.81 (3.96, 5.83) 0.0022 [ref] 0.004
Post 58 3.14 (2.43, 4.07) 0.62 (0.45, 0.85)
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ART among patients in Uganda. Key to the positive
outcomes was the willingness of health workers to parti-
cipate in the interventions to improve service quality.
This way of implementing feasible interventions could
be recommended for roll-out to all ART programs in
Uganda and beyond. Success will largely depend on well-
motivated staff members in the clinics, who are willing to
make operational and workflow changes.
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